Table 5.
EWGSOP2 at baseline, at the end of the intradialytic exercise programme (12 weeks) and 12 weeks after completing the intradialytic exercise programme (24 weeks)
| Control group (n = 33) | Exercise group (n = 18) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | P-value | Baseline | 12 weeks | P-value | 24 weeks | P-value 24 versus 12 weeks | |
| Find: clinical suspicion | ||||||||
| SARC-F (points) | 2.5 ± 2.3 | 2.6 ± 2.3 | .103 | 2.3 ± 2.1 | 1.9 ± 2.00 | .110 | 2.5 ± 2.2 | .056 |
| Assess: loss of strength | ||||||||
| GSD (kg) | 19.6 ± 6.1 | 19.7 ± 6.6 | .855 | 20.9 ± 6.3 | 22.5 ± 6.8 | .019 | 22.9 ± 6.4 | .237 |
| STS-5 (s) | 21.3 ± 7.4 | 23 ± 11.5 | .398 | 19.2 ± 4.9 | 15.9 ± 5.9 | .001* | 14.4 ± 2.9 | .707 |
| Confirm: muscle wasting | ||||||||
| ASM (kg) | 19.5 ± 3.8 | 19.5 ± 3.8 | .795 | 18.9 ± 3.8 | 19.5 ± 3.9 | .010 | 19.2 ± 3.5 | .560 |
| Severity: physical condition | ||||||||
| GS (m/s) | 0.76 ± 0.2 | 0.77 ± 0.3 | .801 | 0.75 ± 0.2 | 0.92 ± 0.3 | .013 | 0.99 ± 0.3 | .267 |
| TUG (s) | 16.2 ± 5.1 | 15.3 ± 5.3 | .392 | 16.02 ± 6.2 | 13.6 ± 7.2 | .041 | 13.5 ± 6.4 | .623 |
| SPPB (points) | 6.4 ± 2.4 | 6.3 ± 2.8 | .732 | 7.2 ± 2.9 | 8.6 ± 2.8 | .027 | 9.6 ± 1.9 | .165 |
Values presented as mean ± SD.
*Statistically significant after Bonferroni correction. Application of Bonferroni's correction to this data set would result in a P-value threshold of .0071 for statistical significance corresponding to an α level of .05 in single testing.